Let's get this right - may need the help of @hottod.
My reading of the agreement is simple and straightforward.
Acadia has worldwide rights to 2591 for Rett's and FragileX - ONLY. Neuren has worldwide rights to any other condition (inclusive of North America).
If so, seems fair and reasonable to both sides afaiac and well done Neuren.
IMO, value will be realised commensurate with the performance of 2591 in the upcoming P2 trial results. Nothing is a given, but it could (realistically) be humongous.
Ann: Q2 2023 quarterly activity and cash flow report, page-12
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.54 |
Change
0.000(0.00%) |
Mkt cap ! $1.559B | |||
| Open | High | Low | Value | Volume |
| $12.61 | $12.68 | $12.32 | $7.219M | 577.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2968 | $12.51 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.57 | 540 | 1 |
View Market Depth
| Last trade - 16.16pm 25/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |